In this article, we will discuss Palonosetron and Renal Impairment. So, let’s get started.
Palonosetron and Renal Impairment
Mild to moderate renal impairment does not significantly affect palonosetron
pharmacokinetic parameters. Total systemic exposure increased by approximately 28% in severe renal impairment relative to healthy subjects. This increase is not considered clinically meaningful.